Effects of OPB-9195, anti-glycation agent, on experimental diabetic neuropathy (Q40700661)

22 September 2017

Effects of OPB-9195, anti-glycation agent, on experimental diabetic neuropathy (English)

1 reference

22 September 2017

Wada R

1

1 reference

22 September 2017

Nishizawa Y

2

1 reference

22 September 2017

Yagihashi N

3

1 reference

22 September 2017

Takeuchi M

4

1 reference

22 September 2017

Ishikawa Y

5

1 reference

22 September 2017

Yasumura K

6

1 reference

22 September 2017

Nakano M

7

1 reference

22 September 2017

Yagihashi S

8

1 reference

22 September 2017

1 June 2001

1 reference

European Journal of Clinical Investigation

22 September 2017

1 reference

22 September 2017

31

1 reference

22 September 2017

513-520

1 reference

22 September 2017

6

1 reference

Glycation of rat sciatic nerve tubulin in experimental diabetes mellitus.

22 September 2017

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2362.2001.00826.X

Nonenzymatic glycosylation of peripheral nerve protein in diabetes mellitus

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2362.2001.00826.X

Excessive nonenzymatic glycosylation of peripheral and central nervous system myelin components in diabetic rats.

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2362.2001.00826.X

Nonenzymatic glycosylation of laminin and the laminin peptide CIKVAVS inhibits neurite outgrowth

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2362.2001.00826.X

Diabetic neuropathy: abnormalities of Schwann cell and perineurial basal laminae. Implications for diabetic vasculopathy

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2362.2001.00826.X

Aminoguanidine prevents diabetes-induced arterial wall protein cross-linking

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2362.2001.00826.X

Diabetic late complications: will aldose reductase inhibitors or inhibitors of advanced glycosylation endproduct formation hold promise?

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2362.2001.00826.X

Aminoguanidine effects on nerve blood flow, vascular permeability, electrophysiology, and oxygen free radicals

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2362.2001.00826.X

Effects of aminoguanidine on peripheral nerve function and polyol pathway metabolites in streptozotocin-diabetic rats

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2362.2001.00826.X

Impaired rat sciatic nerve sodium-potassium adenosine triphosphatase in acute streptozocin diabetes and its correction by dietary myo-inositol supplementation

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2362.2001.00826.X

Hyperglycemia causes oxidative stress in pancreatic beta-cells of GK rats, a model of type 2 diabetes.

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2362.2001.00826.X

Neuropathology and blood flow of nerve, spinal roots and dorsal root ganglia in longstanding diabetic rats.

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2362.2001.00826.X

Assays for 8-hydroxy-2′-deoxyguanosine: A biomarker of in vivo oxidative DNA damage

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2362.2001.00826.X

Advanced glycation end products (AGEs) on the surface of diabetic erythrocytes bind to the vessel wall via a specific receptor inducing oxidant stress in the vasculature: a link between surface-associated AGEs and diabetic complications

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2362.2001.00826.X

Advanced glycation endproducts interacting with their endothelial receptor induce expression of vascular cell adhesion molecule-1 (VCAM-1) in cultured human endothelial cells and in mice. A potential mechanism for the accelerated vasculopathy of dia

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2362.2001.00826.X

Advanced glycosylation products quench nitric oxide and mediate defective endothelium-dependent vasodilatation in experimental diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2362.2001.00826.X

Constitutive nitric oxide synthase expression in retinal vascular endothelial cells is suppressed by high glucose and advanced glycation end products.

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2362.2001.00826.X

Advanced glycation end product (AGE)-mediated induction of tissue factor in cultured endothelial cells is dependent on RAGE.

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2362.2001.00826.X

Advanced glycation end products induce glomerular sclerosis and albuminuria in normal rats

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2362.2001.00826.X

Advanced glycation end products up-regulate gene expression found in diabetic glomerular disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2362.2001.00826.X

BCL-2 expression or antioxidants prevent hyperglycemia-induced formation of intracellular advanced glycation endproducts in bovine endothelial cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2362.2001.00826.X

Administration of an aldose reductase inhibitor induces a decrease of collagen fluorescence in diabetic rats

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2362.2001.00826.X

10.1046/J.1365-2362.2001.00826.X

21 January 2018

Identifiers

DOI

1 reference

22 September 2017

1 reference